Effects of methylprednisolone and dexamethasone on polymorphonuclear leukocyte adherence in vivo. 1987

H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
Department of Medicine, Patras University Medical School, Greece.

It has been proposed that corticosteroids may be effective in the treatment of shock and the adult respiratory distress syndrome (ARDS) by inhibiting complement-induced granulocyte aggregation and by disaggregating granulocyte aggregates in vitro. In the present investigation we have examined the effects of sera from patients who had received comparable doses of methylprednisolone (MP) and dexamethasone (DEX) on the adherence of polymorphonuclear leukocytes (PMNs). Sera obtained from patients that had received MP markedly reduced PMN adherence with maximum effect noted by 8 h. In contrast, sera from patients receiving DEX had no effect on PMN adherence. The results of this study indicate that MP may be more effective in the treatment of septic shock and other conditions associated with microvascular leukostasis.

UI MeSH Term Description Entries
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002561 Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012772 Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status. Endotoxin Shock,Septic Shock,Shock, Endotoxic,Shock, Toxic,Toxic Shock,Toxic Shock Syndrome,Endotoxin Shocks,Shock Syndrome, Toxic,Shock, Endotoxin,Shocks, Endotoxin,Toxic Shock Syndromes

Related Publications

H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
August 1981, Infection and immunity,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
May 1985, Antimicrobial agents and chemotherapy,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
April 2009, Pediatric research,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
January 1992, Clinical therapeutics,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
January 1984, Advances in experimental medicine and biology,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
January 1985, International archives of allergy and applied immunology,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
May 1980, The Journal of laboratory and clinical medicine,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
January 1985, International journal of immunopharmacology,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
April 1993, Oral microbiology and immunology,
H P Bassaris, and P E Lianou, and K N Mallioris, and A T Skoutelis, and E G Votta, and V E Kyriazopoulou, and J T Papavassiliou
January 1986, International archives of allergy and applied immunology,
Copied contents to your clipboard!